

Adult Congenital Heart Association

Webinars Presents:

Atrial Arrhythmias in Adult Congenital Heart Disease

Tuesday, February 13, 2018, 7 p.m. – 8 p.m. EST

Presenters: Jonathan Ginns, MBBS, MD, and George Thomas, MD

About the Webinar

Are you aware that abnormal heart rhythms are a common problem as patients with congenital heart disease get older? When the rhythms come from the top chamber of the heart, they are called atrial arrhythmias. Diagnostic and treatment options have rapidly improved over the past decade. Drs. Jonathan Ginns and George Thomas will talk about the types and causes of these rhythms. They will also discuss how your ACHD cardiology team can prevent and manage the rhythms using the latest technologies. You don't want to miss this webinar. Register now.

REGISTER NOW: <http://bit.ly/2ELo42u>

About the Presenters

Dr. Jonathan Ginns is an adult congenital heart disease cardiologist working at the Weill Cornell ACHD Center at New York Presbyterian Hospital. His interests include clinical cardiology and echocardiography; he also reads cardiac MRI and CT and performs diagnostic cardiac catheterizations.

Dr. George Thomas practices electrophysiology as a full-time faculty member at the Weill Cornell Medical College. He specializes in the treatment of heart rhythm disorders and performs a variety of procedures.

About the Adult Congenital Heart Association

The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to improving the quality of life and extending the lives of adults with congenital heart disease (CHD). ACHA serves and supports the more than one million adults with CHD, their families and the medical community—working with them to address the unmet needs of the long-term survivors of congenital heart defects through education, outreach, advocacy, and promotion of ACHD research. For more information about ACHA, contact (888) 921-ACHA or visit www.achaheart.org.

This webinar is made possible in part by sponsorship support provided by
Actelion Pharmaceuticals US and Gilead Sciences, Inc.